Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report
There is an unmet clinical need for elderly or unfit diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplantation. Lenalidomide is an immunomodulatory agent with antitumor activity in non-Hodgkin lymphoma, with an acceptable toxicity profile and manageable side...
Gespeichert in:
| Veröffentlicht in: | Acta haematologica 2020-12, Vol.143 (6), p.594-597 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 597 |
|---|---|
| container_issue | 6 |
| container_start_page | 594 |
| container_title | Acta haematologica |
| container_volume | 143 |
| creator | Gentilini, Marianna Casadei, Beatrice Broccoli, Alessandro Argnani, Lisa Cavo, Michele Zinzani, Pier Luigi |
| description | There is an unmet clinical need for elderly or unfit diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplantation. Lenalidomide is an immunomodulatory agent with antitumor activity in non-Hodgkin lymphoma, with an acceptable toxicity profile and manageable side effects. A 79-year-old Caucasian male with non-germinal center B-cell-like DLBCL achieved complete remission (CR) after first-line treatment with seven out of eight scheduled cycles of a polychemotherapy containing anthracycline, which had to be discontinued early due to the onset of atrial fibrillation. After 5 months, the patient had an early epicardial relapse. He underwent lenalidomide considering age, cardiological comorbidities, and chronic renal failure. After the third cycle, he achieved CR, confirmed at restaging after the sixth cycle of treatment. Lenalidomide was safe and well tolerated in a patient with atrial fibrillation developed after an anthracycline-based regimen and a relapse of the DLBCL. Moreover, this regimen was effective in a case with a rare extranodal involvement of the epicardium. |
| doi_str_mv | 10.1159/000505716 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_karge</sourceid><recordid>TN_cdi_pubmed_primary_32392556</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32392556</sourcerecordid><originalsourceid>FETCH-LOGICAL-c301t-5171954788467c09f99247562fdce2d1dc7f82d5c595a26965a7b6f087ae3d433</originalsourceid><addsrcrecordid>eNpt0M9LwzAUB_AgipvTg3eRgCcP1SRtksZbV-cmFJWh55I1yaymP0g6cP-9HZ07eXq8x4fvgy8AlxjdYUzFPUKIIsoxOwJjHBEcCMbIMRj3dxxQLsgInHn_1W-Eh-IUjEISCkIpG4OfmVXa2S18aepgnk7hY2nMxmuYSbfWcBqk2lqYbav2s6kkfJNdqesOLrVvm1qV9Rp2Dcx0LW2pmqpUGkrTaQdnbVlIp0ppe2tl6_UDTGAq--SlbhvXnYMTI63XF_s5AR9Ps_d0EWSv8-c0yYIiRLgLKOZY0IjHccR4gYQRgkScMmJUoYnCquAmJooWVFBJmGBU8hUzKOZShyoKwwm4HXIL13jvtMlbV1bSbXOM8l17-aG93l4Ptt2sKq0O8q-uHtwM4HvXjjuAZJEMEXmrTK-u_lX7L7_IQn1v</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report</title><source>Karger Journals</source><source>MEDLINE</source><creator>Gentilini, Marianna ; Casadei, Beatrice ; Broccoli, Alessandro ; Argnani, Lisa ; Cavo, Michele ; Zinzani, Pier Luigi</creator><creatorcontrib>Gentilini, Marianna ; Casadei, Beatrice ; Broccoli, Alessandro ; Argnani, Lisa ; Cavo, Michele ; Zinzani, Pier Luigi</creatorcontrib><description>There is an unmet clinical need for elderly or unfit diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplantation. Lenalidomide is an immunomodulatory agent with antitumor activity in non-Hodgkin lymphoma, with an acceptable toxicity profile and manageable side effects. A 79-year-old Caucasian male with non-germinal center B-cell-like DLBCL achieved complete remission (CR) after first-line treatment with seven out of eight scheduled cycles of a polychemotherapy containing anthracycline, which had to be discontinued early due to the onset of atrial fibrillation. After 5 months, the patient had an early epicardial relapse. He underwent lenalidomide considering age, cardiological comorbidities, and chronic renal failure. After the third cycle, he achieved CR, confirmed at restaging after the sixth cycle of treatment. Lenalidomide was safe and well tolerated in a patient with atrial fibrillation developed after an anthracycline-based regimen and a relapse of the DLBCL. Moreover, this regimen was effective in a case with a rare extranodal involvement of the epicardium.</description><identifier>ISSN: 0001-5792</identifier><identifier>EISSN: 1421-9662</identifier><identifier>DOI: 10.1159/000505716</identifier><identifier>PMID: 32392556</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Aged ; Anthracyclines - administration & dosage ; Anthracyclines - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Atrial Fibrillation - chemically induced ; Atrial Fibrillation - therapy ; Case Report ; Heart Neoplasms - drug therapy ; Heart Neoplasms - pathology ; Humans ; Lenalidomide - administration & dosage ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - pathology ; Male ; Neoplasms, Second Primary - drug therapy ; Neoplasms, Second Primary - pathology ; Pericardium</subject><ispartof>Acta haematologica, 2020-12, Vol.143 (6), p.594-597</ispartof><rights>2020 S. Karger AG, Basel</rights><rights>2020 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c301t-5171954788467c09f99247562fdce2d1dc7f82d5c595a26965a7b6f087ae3d433</citedby><cites>FETCH-LOGICAL-c301t-5171954788467c09f99247562fdce2d1dc7f82d5c595a26965a7b6f087ae3d433</cites><orcidid>0000-0002-2112-2651</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32392556$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gentilini, Marianna</creatorcontrib><creatorcontrib>Casadei, Beatrice</creatorcontrib><creatorcontrib>Broccoli, Alessandro</creatorcontrib><creatorcontrib>Argnani, Lisa</creatorcontrib><creatorcontrib>Cavo, Michele</creatorcontrib><creatorcontrib>Zinzani, Pier Luigi</creatorcontrib><title>Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report</title><title>Acta haematologica</title><addtitle>Acta Haematol</addtitle><description>There is an unmet clinical need for elderly or unfit diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplantation. Lenalidomide is an immunomodulatory agent with antitumor activity in non-Hodgkin lymphoma, with an acceptable toxicity profile and manageable side effects. A 79-year-old Caucasian male with non-germinal center B-cell-like DLBCL achieved complete remission (CR) after first-line treatment with seven out of eight scheduled cycles of a polychemotherapy containing anthracycline, which had to be discontinued early due to the onset of atrial fibrillation. After 5 months, the patient had an early epicardial relapse. He underwent lenalidomide considering age, cardiological comorbidities, and chronic renal failure. After the third cycle, he achieved CR, confirmed at restaging after the sixth cycle of treatment. Lenalidomide was safe and well tolerated in a patient with atrial fibrillation developed after an anthracycline-based regimen and a relapse of the DLBCL. Moreover, this regimen was effective in a case with a rare extranodal involvement of the epicardium.</description><subject>Aged</subject><subject>Anthracyclines - administration & dosage</subject><subject>Anthracyclines - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Atrial Fibrillation - chemically induced</subject><subject>Atrial Fibrillation - therapy</subject><subject>Case Report</subject><subject>Heart Neoplasms - drug therapy</subject><subject>Heart Neoplasms - pathology</subject><subject>Humans</subject><subject>Lenalidomide - administration & dosage</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Male</subject><subject>Neoplasms, Second Primary - drug therapy</subject><subject>Neoplasms, Second Primary - pathology</subject><subject>Pericardium</subject><issn>0001-5792</issn><issn>1421-9662</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0M9LwzAUB_AgipvTg3eRgCcP1SRtksZbV-cmFJWh55I1yaymP0g6cP-9HZ07eXq8x4fvgy8AlxjdYUzFPUKIIsoxOwJjHBEcCMbIMRj3dxxQLsgInHn_1W-Eh-IUjEISCkIpG4OfmVXa2S18aepgnk7hY2nMxmuYSbfWcBqk2lqYbav2s6kkfJNdqesOLrVvm1qV9Rp2Dcx0LW2pmqpUGkrTaQdnbVlIp0ppe2tl6_UDTGAq--SlbhvXnYMTI63XF_s5AR9Ps_d0EWSv8-c0yYIiRLgLKOZY0IjHccR4gYQRgkScMmJUoYnCquAmJooWVFBJmGBU8hUzKOZShyoKwwm4HXIL13jvtMlbV1bSbXOM8l17-aG93l4Ptt2sKq0O8q-uHtwM4HvXjjuAZJEMEXmrTK-u_lX7L7_IQn1v</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Gentilini, Marianna</creator><creator>Casadei, Beatrice</creator><creator>Broccoli, Alessandro</creator><creator>Argnani, Lisa</creator><creator>Cavo, Michele</creator><creator>Zinzani, Pier Luigi</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-2112-2651</orcidid></search><sort><creationdate>20201201</creationdate><title>Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report</title><author>Gentilini, Marianna ; Casadei, Beatrice ; Broccoli, Alessandro ; Argnani, Lisa ; Cavo, Michele ; Zinzani, Pier Luigi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c301t-5171954788467c09f99247562fdce2d1dc7f82d5c595a26965a7b6f087ae3d433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Anthracyclines - administration & dosage</topic><topic>Anthracyclines - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Atrial Fibrillation - chemically induced</topic><topic>Atrial Fibrillation - therapy</topic><topic>Case Report</topic><topic>Heart Neoplasms - drug therapy</topic><topic>Heart Neoplasms - pathology</topic><topic>Humans</topic><topic>Lenalidomide - administration & dosage</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Male</topic><topic>Neoplasms, Second Primary - drug therapy</topic><topic>Neoplasms, Second Primary - pathology</topic><topic>Pericardium</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gentilini, Marianna</creatorcontrib><creatorcontrib>Casadei, Beatrice</creatorcontrib><creatorcontrib>Broccoli, Alessandro</creatorcontrib><creatorcontrib>Argnani, Lisa</creatorcontrib><creatorcontrib>Cavo, Michele</creatorcontrib><creatorcontrib>Zinzani, Pier Luigi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta haematologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gentilini, Marianna</au><au>Casadei, Beatrice</au><au>Broccoli, Alessandro</au><au>Argnani, Lisa</au><au>Cavo, Michele</au><au>Zinzani, Pier Luigi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report</atitle><jtitle>Acta haematologica</jtitle><addtitle>Acta Haematol</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>143</volume><issue>6</issue><spage>594</spage><epage>597</epage><pages>594-597</pages><issn>0001-5792</issn><eissn>1421-9662</eissn><abstract>There is an unmet clinical need for elderly or unfit diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplantation. Lenalidomide is an immunomodulatory agent with antitumor activity in non-Hodgkin lymphoma, with an acceptable toxicity profile and manageable side effects. A 79-year-old Caucasian male with non-germinal center B-cell-like DLBCL achieved complete remission (CR) after first-line treatment with seven out of eight scheduled cycles of a polychemotherapy containing anthracycline, which had to be discontinued early due to the onset of atrial fibrillation. After 5 months, the patient had an early epicardial relapse. He underwent lenalidomide considering age, cardiological comorbidities, and chronic renal failure. After the third cycle, he achieved CR, confirmed at restaging after the sixth cycle of treatment. Lenalidomide was safe and well tolerated in a patient with atrial fibrillation developed after an anthracycline-based regimen and a relapse of the DLBCL. Moreover, this regimen was effective in a case with a rare extranodal involvement of the epicardium.</abstract><cop>Basel, Switzerland</cop><pmid>32392556</pmid><doi>10.1159/000505716</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-2112-2651</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-5792 |
| ispartof | Acta haematologica, 2020-12, Vol.143 (6), p.594-597 |
| issn | 0001-5792 1421-9662 |
| language | eng |
| recordid | cdi_pubmed_primary_32392556 |
| source | Karger Journals; MEDLINE |
| subjects | Aged Anthracyclines - administration & dosage Anthracyclines - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Atrial Fibrillation - chemically induced Atrial Fibrillation - therapy Case Report Heart Neoplasms - drug therapy Heart Neoplasms - pathology Humans Lenalidomide - administration & dosage Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - pathology Male Neoplasms, Second Primary - drug therapy Neoplasms, Second Primary - pathology Pericardium |
| title | Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T03%3A25%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elderly%20Non-GCB%20Diffuse%20Large%20B-Cell%20Lymphoma%20Patient%20Responding%20to%20Lenalidomide%20after%20Epicardial%20Relapse:%20A%20Case%20Report&rft.jtitle=Acta%20haematologica&rft.au=Gentilini,%20Marianna&rft.date=2020-12-01&rft.volume=143&rft.issue=6&rft.spage=594&rft.epage=597&rft.pages=594-597&rft.issn=0001-5792&rft.eissn=1421-9662&rft_id=info:doi/10.1159/000505716&rft_dat=%3Cpubmed_karge%3E32392556%3C/pubmed_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32392556&rfr_iscdi=true |